propidium has been researched along with Alzheimer Disease in 15 studies
Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND AND OBJECTIVE." | 1.37 | Prevention of amyloid-beta oligomer-induced neuronal death by EGTA, estradiol, and endocytosis inhibitor. ( Borutaitė, V; Cižas, P; Jekabsonė, A; Morkūnienė, R, 2011) |
| " Further, this EtOH exposure and withdrawal regimen sensitizes the hippocampus to the toxic effects of Abeta treatment in a manner reflecting over activity of NMDA receptor function." | 1.33 | Ethanol exposure and withdrawal sensitizes the rat hippocampal CA1 pyramidal cell region to beta-amyloid (25-35)-induced cytotoxicity: NMDA receptor involvement. ( Mulholland, PJ; Prendergast, MA; Self, RL; Smith, KJ, 2005) |
| "Irinotecan (CPT-11) is an anticancer drug that occasionally produces acute cholinergic side effects." | 1.30 | The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). ( Dodds, HM; Rivory, LP, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Camps, P | 2 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 2 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 1 |
| Badia, A | 1 |
| Clos, MV | 1 |
| Bartolini, M | 1 |
| Mancini, F | 1 |
| Andrisano, V | 1 |
| Arce, MP | 1 |
| Rodríguez-Franco, MI | 2 |
| Huertas, O | 1 |
| Dafni, T | 1 |
| Luque, FJ | 1 |
| Makhaeva, GF | 1 |
| Kovaleva, NV | 1 |
| Rudakova, EV | 1 |
| Boltneva, NP | 1 |
| Lushchekina, SV | 1 |
| Faingold, II | 1 |
| Poletaeva, DA | 1 |
| Soldatova, YV | 1 |
| Kotelnikova, RA | 1 |
| Serkov, IV | 1 |
| Ustinov, AK | 1 |
| Proshin, AN | 1 |
| Radchenko, EV | 1 |
| Palyulin, VA | 1 |
| Richardson, RJ | 1 |
| Hoppe, JB | 1 |
| Frozza, RL | 1 |
| Horn, AP | 1 |
| Comiran, RA | 1 |
| Bernardi, A | 1 |
| Campos, MM | 1 |
| Battastini, AMO | 1 |
| Salbego, C | 1 |
| Fernández-Bachiller, MI | 1 |
| Pérez, C | 1 |
| González-Muñoz, GC | 1 |
| Conde, S | 1 |
| López, MG | 1 |
| Villarroya, M | 1 |
| García, AG | 1 |
| Cižas, P | 1 |
| Jekabsonė, A | 1 |
| Borutaitė, V | 1 |
| Morkūnienė, R | 1 |
| Boldyrev, A | 1 |
| Koudinov, A | 1 |
| Berezov, T | 1 |
| Carpenter, DO | 1 |
| Boyd-Kimball, D | 1 |
| Sultana, R | 1 |
| Abdul, HM | 1 |
| Butterfield, DA | 1 |
| Self, RL | 1 |
| Smith, KJ | 1 |
| Mulholland, PJ | 1 |
| Prendergast, MA | 1 |
| Mosch, B | 1 |
| Mittag, A | 1 |
| Lenz, D | 1 |
| Arendt, T | 1 |
| Tárnok, A | 1 |
| Musiał, A | 1 |
| Bajda, M | 1 |
| Malawska, B | 1 |
| Inestrosa, NC | 1 |
| Alvarez, A | 1 |
| Pérez, CA | 1 |
| Moreno, RD | 1 |
| Vicente, M | 1 |
| Linker, C | 1 |
| Casanueva, OI | 1 |
| Soto, C | 1 |
| Garrido, J | 1 |
| Dodds, HM | 1 |
| Rivory, LP | 1 |
| Cusack, B | 1 |
| Mallender, WD | 1 |
| El Achab, RE | 1 |
| Morral, J | 1 |
| Rosenberry, TL | 1 |
| Demeester, N | 1 |
| Mertens, C | 1 |
| Caster, H | 1 |
| Goethals, M | 1 |
| Vandekerckhove, J | 1 |
| Rosseneu, M | 1 |
| Labeur, C | 1 |
| Baskys, A | 1 |
| Adamchik, Y | 1 |
1 review available for propidium and Alzheimer Disease
| Article | Year |
|---|---|
Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Topics: Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Galantamine; Huma | 2007 |
14 other studies available for propidium and Alzheimer Disease
| Article | Year |
|---|---|
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
New Multifunctional Agents Based on Conjugates of 4-Amino-2,3-polymethylenequinoline and Butylated Hydroxytoluene for Alzheimer's Disease Treatment.
Topics: Alzheimer Disease; Animals; Antioxidants; Butylated Hydroxytoluene; Cholinesterase Inhibitors; Human | 2020 |
Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Astrocytes; Cell Death; Gly | 2010 |
Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B | 2010 |
Prevention of amyloid-beta oligomer-induced neuronal death by EGTA, estradiol, and endocytosis inhibitor.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; beta-Cyclodextrins; Cells, Cultured; C | 2011 |
Amyloid-beta induced cell death is independent of free radicals.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Animals; Animals, Newborn; Calcium; Car | 2004 |
Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Cell Count; Cells, Cultured; Dipeptides; | 2005 |
Ethanol exposure and withdrawal sensitizes the rat hippocampal CA1 pyramidal cell region to beta-amyloid (25-35)-induced cytotoxicity: NMDA receptor involvement.
Topics: Alcohol Drinking; Alcoholism; Alzheimer Disease; Amyloid beta-Peptides; Animals; Dizocilpine Maleate | 2005 |
Laser scanning cytometry in human brain slices.
Topics: Alzheimer Disease; Brain Chemistry; Cyclin B; Cyclin B1; Entorhinal Cortex; Humans; Image Processing | 2006 |
Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Benzothiazoles; Bi | 1996 |
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
Topics: Acetylcholinesterase; Acylation; Alzheimer Disease; Binding, Competitive; Butyrylcholinesterase; Cam | 1999 |
Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Acylation; Alzheimer Disease; Aminoquinolines; Binding, Competitive; Cholinest | 2000 |
Comparison of the aggregation properties, secondary structure and apoptotic effects of wild-type, Flemish and Dutch N-terminally truncated amyloid beta peptides.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apoptosis; Brain Chemistry; Caspase 3; Caspases; Cerebral | 2001 |
Neuroprotective effects of extracellular glutamate are absent in hippocampal organotypic cultures treated with the amyloid peptide Abeta(25-35).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Androstadienes; Animals; Cell Death; Culture Media, Serum- | 2001 |